2U3 (2U3) News
Follow 2U3 (2U3) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Alcon Acquires Neurotech and Encelto, an FDA-Approved MacTel Type 2 Treatment
EQUITY | Oct 20, 2026, 10:02 PM UTC
L
Alcon Price Target Maintained With a $98.00/Share by Needham
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 10:10 AM UTC
L
White House deal targets lower US drug prices via $19.6B infusion
White House deal with mid-size drugmakers includes a $19.6B infusion into US plants aimed at lowering drug prices.
GEOPOLITICS | Aug 31, 2026, 10:44 PM UTC